Alfa Ica (India) Limited Overview
Alfa Ica (India) Limited is a family-controlled, export-oriented manufacturer of high-pressure decorative laminates (HPL) and compact laminates based in Ahmedabad, Gujarat. Operating from two plants at Sanand with capacity of about 2.1 million sheets a year, the company sells under the "Alfaica" brand, offering a catalogue of more than 600 decors and 50 textures across standard, post-formable, compact, fire-retardant, anti-bacterial, anti-fingerprint, laboratory-grade, exterior and specialty surfaces. Roughly three-quarters or more of sales are exported, chiefly to the UK, Australia, New Zealand, Russia, Israel and Singapore, making the company a niche price-competitive supplier to overseas distributors rather than a domestic consumer brand. With FY2026 revenue of ₹86.6 Cr, net profit of ₹1.9 Cr, a CARE BBB rating and a market value near ₹28 Cr, it is a sub-scale participant in a fragmented industry dominated by Greenlam, Merino and Stylam, competing on breadth of design, European-sourced décor papers and flexibility rather than scale.
What the company does
Alfa Ica manufactures decorative high-pressure laminate sheets and compact laminates. HPL is produced by pressing multiple layers of phenol-resin-saturated kraft paper together with a melamine-resin-impregnated decorative printed paper (and, where required, overlay and underlay papers) under high temperature and pressure. The result is a thin, durable decorative surface used to cover furniture, cabinetry, wall panels, doors, partitions, table and kitchen tops, and, in thicker compact form, as a self-supporting panel for washroom cubicles, laboratory worktops, lockers, exterior cladding and similar high-wear applications (company product descriptions as summarised by Kotak Securities, IIFL and Investing.com).
The company's own description (as reproduced in its annual reports and directors' reports, FY2025) emphasises that the Alfa range comprises more than 600 design decors and more than 50 textures, and that the laminates are recognised by architects, interior designers and fitters. Its marketing positions all decorative papers as sourced from premier European printers and its products as conforming to the EN 438 European HPL standard (Groww company profile, citing company disclosures). The company describes itself as a Government-recognised Star Export House holding ISO 9001 and ISO 14001 certifications (CARE Ratings, Dec 2025).
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue type | ~100% product sales (manufactured laminate sheets and compacts); no service, subscription or licensing revenue disclosed | Single-line revenue in results; no segment reporting (Sharpely, Screener) |
| Sales mix by geography | Exports ~78% of gross sales (FY2025), ~77% (FY2024), ~75% (FY2023) | CARE Ratings Dec 2025 |
| Export incentives / other operating revenue | "Revenue as reported" exceeds operating revenue by ~₹0.9–2.0 Cr p.a., consistent with export incentives and other operating income | StockAnalysis.com (S&P) FY2022–FY2026 |
| Brand | "Alfaica" | CARE Ratings |
| Customer types | Overseas importers/distributors of surfacing materials, furniture and fit-out fabricators, domestic dealers; architects and interior designers as specifiers | CARE Ratings; company descriptions; Panjiva (US importer Decotone Surfaces) |
| End-markets | Residential furniture and interiors, commercial interiors (offices, shops), institutional (schools – chalk/marker boards; hospitals – anti-bacterial; laboratories), washrooms/cubicles, exterior façades | Investing.com company description |
| Value-chain position | Mid-stream converter: buys imported kraft and décor papers plus melamine and phenol/formaldehyde chemicals; sells finished sheets to distribution | CARE Ratings Dec 2025 |
| Procurement | Imports ≈40% of raw material cost (kraft and décor papers, melamine); paper lead times 2–6 months, forcing high inventories | CARE Ratings Dec 2025 |
| Hedging | Natural hedge as net exporter; no active FX hedging policy | CARE Ratings Dec 2025 |
Independent characterisation
Alfa Ica is best understood as a contract-style, export-led, design-breadth manufacturer operating at the small end of the Indian laminate industry. Its economic engine is the spread between export realisations (largely USD/GBP/AUD-linked) and the cost of imported paper and petrochemical-derived resins, minus the carrying cost of a large, slow-turning paper inventory. Unlike Greenlam or Merino, which invest heavily in domestic brand-building, dealer networks and showroom formats, Alfa Ica's distribution is concentrated among a limited number of overseas buyers. This structure explains three persistent features of its financials: (i) thin EBITDA margins of roughly 5–6.5% (versus 11–19% for the listed leaders); (ii) a long cash conversion cycle of 100–155 days; and (iii) meaningful sensitivity of reported profit to foreign-exchange gains, which have frequently represented a large share of pre-tax profit (S&P data show FX gains of ₹0.84 Cr in FY2025 and ₹1.94 Cr in FY2026 against PBT of ₹1.92 Cr and ₹2.54 Cr respectively).
The business is also exposed to credit risk at the customer level: in FY2025–FY2026 the company had to write off most of a ₹2.68 Cr receivable from International Decorative Surfaces, a UK distributor that entered administration (CARE Ratings, Dec 2025). Given annual net profit of only ₹1.4–1.9 Cr, a single customer failure of that magnitude can eliminate more than a year of earnings.
Strategy
Stated strategy
The company does not publish a formal strategy document, investor-day material or medium-term targets. Themes recurring in its annual reports and directors' reports include: (i) continuous introduction of new designs and finishes to serve interior decorators and furniture designers; (ii) maintaining quality certifications (ISO 9001, ISO 14001) and export-house status; (iii) sourcing décor papers from premier European printers to meet EN 438; and (iv) prudence in capital allocation, historically expressed as conserving resources rather than paying dividends.
Inferred strategic initiatives (last 24 months)
| Initiative | Evidence | Status / assessment |
|---|---|---|
| Capacity/plant investment | Capex of ~₹5.0 Cr in FY2025, net fixed assets +₹4.4 Cr; CWIP of ₹0.76 Cr at FY2024 capitalised | Completed; depreciation up 36% in FY2025 |
| Brand and marketing investment | Advertising expense rose from ₹0.10 Cr (FY2023) to ₹0.78 Cr (FY2025) and ₹0.68 Cr (FY2026) (S&P) | Ongoing; ~0.8% of revenue |
| Product-mix upgrade toward compacts and specialty grades | CARE (2019) cited higher share of thick laminates; portfolio now includes cubicle compacts, exterior façades, fire-retardant, lab-grade | Ongoing |
| Leadership formalisation | MD/JMD re-designations (Oct 2025) | Completed |
| Working-capital tightening | CCC cut from 155 to 102 days (FY2023–FY2026) | Delivered |
| Credit-risk management after UK distributor failure | ~60% of ₹2.68 Cr written off; balance to be written off | In progress |
Sustainability, cost programmes, guidance
No ESG targets, formal cost-reduction programmes, partnerships or new business launches have been announced. Management guidance: none published. The only forward-looking benchmarks available are CARE's rating sensitivities — upgrade triggers of sustained PBILDT margins above 10% and net worth above ₹75 Cr; downgrade triggers of an operating cycle above 125 days, PBILDT interest coverage below 2.5x or TD/PBILDT above 3x.
Products & Services
All products sit within the single laminates segment and are sold under the Alfaica brand. The company does not publish prices, launch years or version histories; these are marked accordingly.
Sources: Simply Wall St and Investing.com company descriptions (S&P / Refinitiv profiles); Kotak Securities / IIFL company summaries; Groww profile; CARE Ratings.
Portfolio observations. Breadth is the principal selling proposition: >600 decors is comparable to larger domestic players' catalogues and is vital for export distributors who need range depth. CARE noted as early as Dec 2019 that a rising share of higher-value thick laminates lifted margins in FY2019, implying a strategic tilt toward compacts and specialty grades. Notably absent from the portfolio (versus Greenlam/Stylam) are plywood, particle board, veneers, engineered wood flooring, solid surfaces, PU-lacquer-coated panels and acrylic/PVC laminates — limiting cross-selling opportunities.
Product Portfolio
| Product line | Description / key capabilities | Typical applications / target customer | Launch year | Pricing model |
|---|---|---|---|---|
Standard decorative HPL (general purpose) | Multi-layer phenolic kraft core with melamine-impregnated décor paper; >600 decors, >50 textures; produced to EN 438 | Furniture covering, cabinets, wardrobes, doors, wall panelling; furniture makers, distributors | Core product since inception | Not disclosed (per-sheet distributor pricing typical) |
Post-formable laminates | Thinner grade engineered to bend around rounded edges under heat; company material indicates post-forming capability up to about 3 mm radius-type applications | Kitchen counter edges, rounded table tops, furniture edges | — | — |
Compact grade laminates | Thick self-supporting HPL with décor on both faces; usable for horizontal and vertical applications without substrate | Table tops, partitions, furniture panels, institutional fit-outs | — | — |
Cubicle compact / cubicle partition panels | Moisture-resistant compact panels for washroom and changing-room cubicles | Commercial washrooms, schools, gyms, malls | — | — |
Colour core / colour compact laminates | Through-coloured core so that machined edges show matching colour | Premium furniture, retail fixtures | — | — |
Interior grade and exterior grade (façade) laminates | Exterior grade engineered for weather and UV resistance; offered as exterior façade/cladding panels | Building façades, exterior wall cladding; architects, façade contractors | — | — |
Interior tile panels | Decorative laminate-faced tile/panel formats for walls | Interior wall panelling in commercial spaces | — | — |
Tough gloss laminates | High-gloss, scuff-resistant range | Shops, offices, homes — premium display surfaces | — | — |
Anti-fingerprint laminates | Matte super-surface resisting fingerprint marks | Kitchens, premium furniture | — | — |
Anti-bacterial laminates | Surfaces treated to inhibit bacterial growth | Hospitals, clinics, kitchens, hygiene-sensitive areas | — | — |
Laboratory grade laminates | Chemical-resistant surfaces | School/industrial/medical laboratory worktops | — | — |
Fire retardant laminates | Formulated to meet fire-performance requirements | Public buildings, transport interiors, hotels | — | — |
Flooring grade laminates | High wear-resistance grade | Flooring applications | — | — |
Real metal foil laminates | Laminates surfaced with real metal foils giving metallic lustre | Retail and hospitality feature walls, furniture accents | — | — |
Dry wipe / white marker boards | Writable laminate surfaces | Schools, offices | — | — |
Green chalk board laminates | Chalk-writable laminate surfaces | Schools and colleges | — | — |
Shower panels / wet-area panels | Moisture-resistant panels | Bathrooms, wet areas | — | — |
“—” = not publicly disclosed.
Financial Narrative
Primary source: Screener.in standalone financials compiled from BSE-filed audited results (FY2022–FY2026); supplementary data from StockAnalysis.com (S&P Global Market Intelligence, last updated 8 Aug 2026). Ratios marked "computed" are analyst calculations from these figures.
Income statement
Note on gross profit: S&P's "cost of revenue" includes only materials consumed; the FY2026 figure was restated from ₹34.20 Cr to ₹33.47 Cr between two S&P data snapshots. Gross margin should be read as a materials-spread indicator, not a conventional gross margin.
Margin profile
CARE's PBILDT margin is computed on total operating income (incl. export incentives) and differs from Screener's operating margin (which excludes other operating income); FY2024–FY2025 CARE values shown for reference.
Revenue CAGR: FY2022–FY2026 (4-year) = 2.0%; FY2021–FY2026 (5-year, from ₹55.17 Cr) = 9.45%; 10-year (Screener) = 6%. TTM to June 2026: ₹96.77 Cr, +23%.
Commentary — income statement. The five-year record shows a business with volatile top-line but remarkably stable absolute earnings. Revenue swung from a pandemic-restocking peak of ₹80 Cr in FY2022 to ₹65 Cr in FY2023, then recovered for three consecutive years to a new high of ₹86.6 Cr in FY2026; the trailing twelve months to June 2026 reached ₹96.8 Cr after a record Q1 FY2027 (₹29.72 Cr). Yet absolute EBITDA has been trapped in a ₹4.0–4.4 Cr band throughout, meaning incremental revenue has delivered almost no incremental operating profit. The operating margin compressed from 6.3% in FY2023 to 4.8% in FY2026, and to 4.4% on a TTM basis, despite S&P's materials spread widening to ~39–41%. The explanation lies in the "other operating expenses" line, which rose from ₹17.4 Cr (FY2023) to ₹26.1 Cr (FY2026) per S&P — consistent with higher power, freight, employee and selling costs, and with a step-up in advertising from ₹0.10 Cr (FY2023) to ₹0.78 Cr (FY2025) and ₹0.68 Cr (FY2026).
Below EBITDA, two forces offset each other: interest cost rose by 27% from FY2024 to FY2025 as working-capital borrowings increased, and depreciation jumped 36% after the FY2025 capex; but other income — dominated by foreign-exchange gains as the rupee weakened — more than doubled to ₹1.94 Cr in FY2026. The quality-of-earnings conclusion is important: in FY2026, other income equalled 76% of PBT. Excluding FX, the core business would have earned a pre-tax profit of roughly ₹0.6 Cr. Net profit growth of 32% in FY2026 was therefore largely currency-driven rather than operational.
Quarterly trajectory (last 9 quarters)
Source: Screener.in (BSE quarterly results). Discrepancy note: one news aggregator (ScanX) reported Q1 FY2027 net profit of ₹1.02 Cr on revenue of ₹30.08 Cr; the company's standalone filing as relayed by Capital Market and ScanX's own second article show net profit of ₹76.56 lakh on revenue from operations of ₹2,972.02 lakh. The ₹0.77 Cr figure is adopted as primary.
Quarterly commentary. The last three quarters mark a clear volume inflection — sales rose from ₹19 Cr in Q2 FY2026 to ₹22 Cr, ₹26 Cr and ₹30 Cr — but margins have not followed. Q4 FY2026 was particularly weak at the operating line (OPM 1.97%), rescued by ₹1.10 Cr of other income. Q1 FY2027 returned to a 5% OPM. Whether the revenue surge reflects new export customers, price increases passed through on resin inflation (larger peers implemented 12–15% laminate price hikes in FY2026 per Greenlam's commentary), or a one-off order is not disclosed.
Balance sheet
Items not separately disclosed in reviewed sources: cash and cash equivalents at each year-end (CARE reports only ₹0.59 Cr at 30 Sep 2025; Screener's annual net cash flows of between −₹0.13 Cr and +₹0.25 Cr imply cash balances consistently below ₹1 Cr); short-term vs long-term debt split (CARE indicates borrowings are predominantly fund-based working-capital facilities — cash credit/packing credit of ₹12 Cr sanctioned — plus unsecured loans from promoters and relatives, with nil scheduled term-debt repayment); and working capital in absolute terms. Given negligible cash, net debt ≈ gross borrowings (₹16.8 Cr at FY2026).
Cash flow
Source: Screener.in cash-flow statements (BSE annual reports). CARE separately reports FY2025 CFO of ₹1.96 Cr (vs Screener ₹1.87 Cr — minor classification difference).
Commentary — cash flow. Cash generation alternates with the working-capital cycle: years of revenue acceleration (FY2022, FY2025) consume cash as inventory and receivables build, while years of stabilisation (FY2023, FY2024, FY2026) release it. Cumulative five-year FCF is +₹4.6 Cr against cumulative net profit of ₹8.1 Cr — a 57% conversion, reflecting the capital intensity of carrying imported paper stock. FY2025 was the heaviest investment year in the period (₹5.0 Cr capex, lifting net fixed assets by 29%), funded by incremental borrowings of ₹5 Cr; FY2026 FCF of ₹4.0 Cr was used to repay ₹2.2 Cr of debt and fund interest. The company has paid no dividend since FY2019 and has never conducted a buyback.
Ratio analysis
Current ratio: not publicly disclosed in reviewed sources (the current-asset/current-liability split was not available; CARE describes liquidity as "adequate" with ~70% average utilisation of working-capital limits over the 12 months to Oct 2025). Ratios use Screener inventory-day conventions; CARE computes FY2025 operating cycle at 103 days (inventory 79, collection 51) versus 111 days in FY2024 — methodology differs.
Commentary — ratios. Returns are structurally below the cost of equity: ROE of 6–9% and ROIC of 7–8% compare unfavourably with an Indian small-cap cost of equity in the low-to-mid teens, which is consistent with the stock trading close to book value (P/B ~1.1x). The single most encouraging trend is the cash conversion cycle, which has shortened from 155 days (FY2023) to 102 days (FY2026), driven by lower inventory days and stretched payables — an important improvement given CARE's negative rating trigger of an operating cycle above 125 days. Leverage metrics, however, sit uncomfortably close to CARE's other negative triggers: CARE's own PBILDT interest coverage fell to 2.59x in FY2025 and 2.40x in H1 FY2026, already below the 2.5x downgrade sensitivity, while gross debt/EBITDA on Screener data (4.1x) exceeds the agency's 3x threshold (though CARE's definition of debt is narrower).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Segment (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Decorative laminates – revenue from operations | 68.49 | 78.56 | 86.64 |
Decorative laminates – operating profit (EBITDA, excl. other income) | 4.06 | 4.43 | 4.14 |
Decorative laminates – profit before tax | 2.23 | 1.92 | 2.54 |
Operating (EBITDA) margin % | 5.93 | 5.64 | 4.78 |
YoY revenue growth % | 5.96 | 14.70 | 10.29 |
Contribution to total revenue % | 100 | 100 | 100 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 79.98 | 64.64 | 68.49 | 78.56 | 86.64 |
Revenue growth YoY (%) | 44.96 | -19.19 | 5.96 | 14.70 | 10.29 |
Gross profit – S&P definition (INR Cr) | 28.74 | 23.91 | 26.18 | 31.86 | 33.47 |
Operating profit / EBITDA excl. other income (INR Cr) | 4.39 | 4.07 | 4.06 | 4.43 | 4.14 |
Other income incl. FX gains (INR Cr) | 0.40 | 0.55 | 0.80 | 0.88 | 1.94 |
Depreciation (INR Cr) | 1.01 | 1.04 | 0.99 | 1.35 | 1.46 |
EBIT = PBT + interest (INR Cr, computed) | 3.78 | 3.58 | 3.87 | 3.96 | 4.62 |
Interest expense (INR Cr) | 1.59 | 1.63 | 1.64 | 2.04 | 2.08 |
Profit before tax (INR Cr) | 2.19 | 1.95 | 2.23 | 1.92 | 2.54 |
Tax rate (%) | 25.57 | 25.13 | 24.66 | 25.00 | 25.59 |
Net profit (INR Cr) | 1.63 | 1.46 | 1.68 | 1.44 | 1.90 |
EPS basic (INR) | 4.03 | 3.61 | 4.16 | 3.56 | 4.70 |
EPS diluted (INR) | 4.03 | 3.61 | 4.16 | 3.56 | 4.70 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin – S&P (%) | 35.93 | 36.99 | 38.23 | 40.56 | 38.63 |
EBITDA margin excl. other income (%) | 5.49 | 6.30 | 5.93 | 5.64 | 4.78 |
EBIT margin incl. other income (%, computed) | 4.73 | 5.54 | 5.65 | 5.04 | 5.33 |
Pre-tax margin (%) | 2.74 | 3.02 | 3.26 | 2.44 | 2.93 |
Net margin (%) | 2.04 | 2.26 | 2.45 | 1.83 | 2.19 |
CARE PBILDT margin (%) | — | — | 7.01 | 6.64 | — |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric (INR Cr) | Q1FY2025 | Q2FY2025 | Q3FY2025 | Q4FY2025 | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|---|---|---|---|
Sales | 19.51 | 18.42 | 20.26 | 20.37 | 19.59 | 18.98 | 22.17 | 25.90 | 29.72 |
Operating profit | 1.30 | 1.29 | 0.05 | 1.71 | 1.31 | 1.06 | 1.16 | 0.51 | 1.51 |
OPM (%) | 6.66 | 7.00 | 0.25 | 8.39 | 6.69 | 5.58 | 5.23 | 1.97 | 5.08 |
Other income | 0.00 | 0.18 | 0.18 | 0.51 | 0.21 | 0.37 | 0.27 | 1.10 | 0.36 |
Interest | 0.42 | 0.53 | 0.55 | 0.44 | 0.50 | 0.49 | 0.55 | 0.45 | 0.46 |
Depreciation | 0.30 | 0.34 | 0.35 | 0.36 | 0.36 | 0.36 | 0.36 | 0.38 | 0.38 |
PBT | 0.58 | 0.60 | -0.67 | 1.42 | 0.66 | 0.58 | 0.52 | 0.78 | 1.03 |
Net profit | 0.42 | 0.48 | -0.54 | 1.08 | 0.50 | 0.45 | 0.39 | 0.56 | 0.77 |
EPS (INR) | 1.04 | 1.19 | -1.34 | 2.67 | 1.24 | 1.11 | 0.97 | 1.39 | 1.91 |
Balance Sheet and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 44.91 | 40.00 | 44.59 | 48.53 | 52.59 |
Net fixed assets | 13.71 | 14.43 | 15.16 | 19.57 | 19.92 |
Capital work in progress | 0.00 | 0.00 | 0.76 | 0.00 | 0.00 |
Other (mainly current) assets | 31.20 | 25.57 | 28.67 | 28.96 | 32.67 |
Goodwill & intangibles | 0 | 0 | 0 | 0 | 0 |
Equity share capital | 4.04 | 4.04 | 4.04 | 4.04 | 4.04 |
Reserves | 14.57 | 16.05 | 17.73 | 19.18 | 21.09 |
Total shareholders' equity | 18.61 | 20.09 | 21.77 | 23.22 | 25.13 |
Total borrowings | 17.44 | 14.98 | 14.04 | 19.00 | 16.84 |
Other liabilities (incl. trade payables) | 8.86 | 4.93 | 8.78 | 6.31 | 10.62 |
Book value per share (INR, computed) | 46.06 | 49.73 | 53.89 | 57.48 | 62.20 |
Cash Flow and Margin Analysis (%)
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities | -1.34 | 5.75 | 5.21 | 1.87 | 5.85 |
Capital expenditure (computed = CFO − FCF) | 1.73 | 1.76 | 2.49 | 4.98 | 1.82 |
Free cash flow | -3.07 | 3.99 | 2.72 | -3.11 | 4.03 |
Cash from investing activities | -1.73 | -1.75 | -2.48 | -4.96 | -1.81 |
Cash from financing activities | 3.11 | -4.02 | -2.47 | 3.03 | -4.17 |
Net change in cash | 0.04 | -0.03 | 0.25 | -0.06 | -0.13 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
CFO / operating profit (%) | -17 | 152 | 140 | 52 | 152 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, net profit / average equity, computed) | 9.16 | 7.55 | 8.03 | 6.40 | 7.86 |
ROA (%, net profit / average assets, computed) | 3.95 | 3.44 | 3.97 | 3.09 | 3.76 |
ROCE (%, Screener) | 11.66 | 10.07 | 10.98 | 10.10 | 11.00 |
ROIC (%, NOPAT / period-end equity + debt, computed) | 7.79 | 7.64 | 8.13 | 7.04 | 8.19 |
Debt / equity (x, Screener basis) | 0.94 | 0.75 | 0.64 | 0.82 | 0.67 |
Overall gearing (x, CARE basis) | — | — | 0.34 | 0.50 | — |
Gross debt / EBITDA (x, computed) | 3.97 | 3.68 | 3.46 | 4.29 | 4.07 |
Interest coverage – EBIT / interest (x, computed) | 2.38 | 2.20 | 2.36 | 1.94 | 2.22 |
PBILDT interest coverage (x, CARE) | — | — | 2.97 | 2.59 | — |
Asset turnover (x, revenue / average assets) | 1.94 | 1.52 | 1.62 | 1.69 | 1.71 |
Debtor days | 56.95 | 42.24 | 51.91 | 55.94 | 57.00 |
Inventory days | 117.58 | 144.93 | 138.29 | 107.49 | 102.41 |
Payable days | 53.75 | 32.07 | 57.14 | 36.83 | 57.09 |
Cash conversion cycle (days) | 120.79 | 155.09 | 133.06 | 126.60 | 102.32 |
Working capital days | 48.47 | 65.11 | 61.87 | 51.06 | 49.08 |
Revenue by Region (%) and Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Export share of gross sales (%, CARE) | 75 | 77 | 78 |
Export revenue (INR Cr) | — | 51.61 | 59.59 |
Domestic share of gross sales (%, derived) | 25 | 23 | 22 |
Region Overview
| Region | Countries named | Source |
|---|---|---|
Europe | United Kingdom (key market; also site of the insolvent distributor International Decorative Surfaces), Russia | CARE Dec 2025 |
Middle East | Israel | CARE Dec 2025 |
Asia-Pacific | Australia, New Zealand, Singapore | CARE Dec 2025; ICICI Direct profile |
Americas | United States (US importer Decotone Surfaces appears in US customs bills of lading 2019 and 2023; a ₹0.34 Cr receivable from a US-based entity was overdue >6 months as of Dec 2025) | Panjiva; CARE Dec 2025 |
India (domestic) | Not broken down by state | — |
Capital Markets
| Measure | Value | Source |
|---|---|---|
Last close | ₹70.10 (16 Oct 2026) | StockAnalysis.com |
52-week high / low | ₹101 / ₹67.8 | Screener.in (30 Sep 2026) |
1-year return | −10% (to 30 Sep 2026) | Screener.in |
3-year price CAGR | 12% | Screener.in |
5-year price CAGR | 17% | Screener.in |
10-year price CAGR | 8% | Screener.in |
Average weekly volatility | 11.7% vs 5.3% market average | Simply Wall St |
Trading venue / liquidity | BSE X-group; very thin volumes | MarketsMojo; BSE |
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Book value per share (INR) | 46.06 | 49.73 | 53.89 | 57.48 | 62.20 |
EPS (INR) | 4.03 | 3.61 | 4.16 | 3.56 | 4.70 |
Dividend payout (%) | 0 | 0 | 0 | 0 | 0 |
Valuation Multiples
| Multiple | Alfa Ica | Basis |
|---|---|---|
Market capitalisation | ≈ ₹28.3 Cr | 4.04 M shares |
Enterprise value | ≈ ₹44.6–45.1 Cr | Market cap + FY2026 borrowings ₹16.84 Cr − cash (<₹0.6 Cr assumed per CARE Sep 2025) |
P/E (TTM EPS ₹5.38) | ≈ 13.0x | Screener TTM to Jun 2026 |
P/E (FY2026 EPS ₹4.70) | ≈ 14.9x | — |
P/B (BV ₹62.2) | ≈ 1.13x | FY2026 |
EV/EBITDA (TTM EBITDA ≈ ₹4.24–4.26 Cr) | ≈ 10.5x | Screener/S&P TTM |
EV/Sales (TTM ₹96.8 Cr) | ≈ 0.46x | — |
Dividend yield | 0% | — |
Dividend History
| Year | Dividend payout ratio | Implied DPS |
|---|---|---|
FY2015–FY2017 | 0% | Nil |
FY2018 | 34.24% | ≈ ₹1.0 (derived from EPS ₹2.92; not company-confirmed) |
FY2019 | 32.32% | ≈ ₹1.0 (derived from EPS ₹3.09; not company-confirmed) |
FY2020–FY2026 | 0% | Nil |
Analyst Conclusions
Management guidance and consensus
Management provides no financial guidance, and there is no analyst consensus. The nearest forward indicators are: (i) the run-rate of the last three quarters (₹22.2 Cr → ₹25.9 Cr → ₹29.7 Cr), which annualises above ₹100 Cr; (ii) CARE's stable outlook, premised on experienced promoters and the established Alfaica brand; and (iii) industry growth of ~4–5% p.a. in both Indian and global HPL markets.
Bull case
-
Volume breakout with operating leverage. Q1 FY2027 revenue of ₹29.72 Cr (+52%) implies the company may be winning new export accounts or share; if EBITDA margin merely returns to the FY2023 level of 6.3% on ₹110 Cr of revenue, EBITDA would reach ~₹7 Cr — 65% above the five-year plateau — with net profit potentially exceeding ₹3.5 Cr (EPS ~₹9), making the current ₹70 price ~8x forward earnings.
-
Balance sheet discipline improving. The cash conversion cycle fell 53 days in three years and FY2026 FCF of ₹4.0 Cr allowed ₹2.2 Cr of debt reduction; continued improvement would lift coverage back above CARE's 2.5x threshold and lower interest costs.
-
Asset-backed valuation. At ~1.1x book and ~0.46x EV/sales, the stock prices in near-zero growth; the FY2025 capex has been absorbed, depreciation is stable at ~₹1.5 Cr, and promoter ownership of 71% aligns management with minority holders.
Bear case
-
Growth without profit. Absolute EBITDA has been flat at ₹4.0–4.4 Cr for five years; FY2026 OPM fell to 4.8% and Q4 FY2026 to 2.0%. The revenue surge may be price-led pass-through of resin inflation rather than real volume, with no margin benefit.
-
Low-quality earnings. FX gains accounted for ~76% of FY2026 PBT; a stable or appreciating rupee would cut reported profit by more than half. Simultaneously, CARE coverage of 2.40x is already below the downgrade trigger.
-
Customer and governance risk. A single UK distributor failure wiped out more than a year's profit; exposure to Russia and Israel adds tail risk. Two Company Secretary changes in 13 months, a 44% unexplained drop in shareholder count, and MD pay increases with no dividend for seven years weigh on minority-investor confidence.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Q2 FY2027 results | ~Nov 2026 | Whether ₹25–30 Cr quarterly revenue sustains; OPM recovery toward 6%+ |
| CARE annual surveillance | ~Dec 2026 | Rating retention given coverage below 2.5x; any outlook change |
| Write-off of remaining UK receivable (~₹1.1 Cr) | FY2027 | Size and timing of residual charge |
| INR/USD, INR/GBP, INR/AUD movements | Continuous | FX gain/loss contribution to other income |
| Resin, melamine, kraft paper prices | Continuous | Gross spread and pass-through |
| Capacity announcements | Any | Expansion beyond 21 lakh sheets would signal confidence in demand |
| Shareholder register / governance | Quarterly | Explanation for shareholder-count drop; CS stability; any dividend resumption |
| Q3 FY2027 and FY2027 results | Feb 2027; May 2027 | Full-year revenue >₹100 Cr and EBITDA >₹5 Cr would break the multi-year plateau |
Analyst verdict
Alfa Ica (India) Limited is a durable but structurally low-return niche exporter. Its thirty-five-year survival, unbroken record of annual profits, broad design library and export-house credentials demonstrate genuine operational competence; few Indian micro-cap manufacturers have navigated the global financial crisis, COVID and successive raw-material cycles without a loss year. Yet the financial record also shows a company that has not converted that competence into economic value. Revenue grew at about 9% a year over FY2021–FY2026, but absolute EBITDA did not grow at all, returns on equity have stayed in single digits, and in FY2026 the majority of pre-tax profit came from currency gains rather than the laminate business itself.
The recent revenue acceleration — a record ₹29.7 Cr in Q1 FY2027, with trailing revenue near ₹97 Cr — is the most important development in years and is the hinge of any investment case. If it reflects durable new export volume and the company can restore 6–7% EBITDA margins, earnings could roughly double and the shares, at ~13x trailing earnings and ~1.1x book, would look inexpensive. If instead it reflects price pass-through or a lumpy order, the margin data already suggest the extra revenue will not reach the bottom line.
Credit metrics argue for caution: CARE interest coverage sits below its own downgrade trigger, debt equals about four times EBITDA, and a single distributor insolvency in the UK erased more than a year of profit. Governance — family control, rising executive pay, no dividends since FY2019, frequent Company Secretary turnover and an unexplained halving of the shareholder register — warrants scrutiny. Extreme illiquidity further limits institutional suitability.
Verdict: a speculative, deep-value micro-cap whose re-rating depends entirely on proving that its new revenue run-rate carries margin. Monitor Q2 and Q3 FY2027 OPM and the December 2026 CARE review before forming a constructive view; absent margin improvement, the stock merits a neutral-to-cautious stance.
APPENDIX A — DATA DISCREPANCIES NOTED
| Item | Source A | Source B | Treatment |
|---|---|---|---|
| Q1 FY2027 net profit | ₹0.77 Cr (₹76.56 lakh; Capital Market, ScanX article 2) | ₹1.02 Cr (ScanX headline) | ₹0.77 Cr adopted (matches standalone filing figures) |
| FY2024 export share | ~77% of gross sales (CARE) | 75.35% (₹51.61 Cr; Groww/company) | Both shown; denominator difference likely |
| Leverage FY2025 | D/E 0.82x (Screener) | Gearing 0.50x (CARE) | Both shown; CARE likely treats promoter loans as quasi-equity |
| FY2025 CFO | ₹1.87 Cr (Screener) | ₹1.96 Cr (CARE) | Screener used in tables |
| FY2026 gross profit (S&P) | ₹34.20 Cr (earlier snapshot) | ₹33.47 Cr (later snapshot) | Later figure used |
| Operating cycle FY2025 | CCC 126.6 days (Screener) | 103 days (CARE) | Both shown; methodology differs |
| Shyamal Raval classification | Non-Executive Director | Independent Director (one extract) | Flagged as inconsistent |
| Q3 FY2026 board meeting date | 5 Feb 2026 (Screener) | 6 Feb 2026 (Value Research intimation) | 5 Feb 2026 used (outcome date) |
| BSE listing date | Oct 2004 (S&P data) | IPO date not disclosed | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / key dates | Background | Age | Compensation |
|---|---|---|---|---|---|
Rishi Tikmani (DIN 00638644) | Managing Director (from 1 Oct 2025; previously Whole-time / Executive Director) | Executive Director since at least 2009; re-appointed 2012; MD term 1 Oct 2025 – 30 Sep 2028 | Son of founder Rajendra Tikmani; BBA (Gujarat University) and MBA in International Business; >10 years' experience per CARE | 43 (per Aug 2025 BSE filing) | Total ₹5.4 M (FY2024, S&P via Simply Wall St); ₹5.4 M director remuneration also recorded in FY2020 related-party note; increase approved at Sep 2026 AGM effective 1 Aug 2026 (amount not disclosed in reviewed sources) |
Pooja Tikmani (DIN 06944249) | Women Joint Managing Director (from 1 Oct 2025; previously Woman Executive Director) | Joined as Purchase Manager (2009); director since at least FY2019; JMD term 1 Oct 2025 – 30 Sep 2028 | Daughter of founder; sister of Rishi Tikmani; oversees purchasing/operations | 43 (per Aug 2025 BSE filing) | ₹5.4 M director remuneration recorded in FY2020; current not disclosed; increase approved Sep 2026 |
Hansraj Sekhani | Chief Financial Officer | CFO since at least FY2019 | — | — | — |
Himadri Trivedi | Company Secretary (May 2019 – Sep 2025) | Appointed 9 May 2019; resignation filed 30 Sep 2025 | — | — | — |
Dhara Mistry | Company Secretary & Compliance Officer (Sep/Oct 2025 – Oct 2026) | Resignation considered at 3 Oct 2026 board meeting | — | — | — |
Himandri Shah | Company Secretary & Compliance Officer (appointment considered 3 Oct 2026) | New appointee | — | — | — |
“—” = not publicly disclosed.
Board of Directors
| Director | Category | Notes |
|---|---|---|
Rishi Tikmani | Executive – Managing Director (promoter) | Member of board committees |
Pooja Tikmani | Executive – Women Joint Managing Director (promoter) | Retired by rotation and re-appointed at 2025 AGM |
Shyamal Raval | Non-Executive Director (appointed FY2025) | Retired by rotation and re-appointed at 35th AGM (21 Sep 2026); one extract describes him as Independent — classification inconsistent across sources |
Ayush Kedia | Independent Director | Chairs a board committee (likely Audit or Nomination & Remuneration) |
Poonam Panchal | Independent Director (appointed FY2025) | Committee member |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
FY2025 | Appointment of Shyamal Raval (NED) and Poonam Panchal (ID) | Board refresh replacing long-tenured IDs |
23 Aug 2025 (effective 1 Oct 2025) | Rishi Tikmani re-designated MD; Pooja Tikmani re-designated Women JMD, both for three years | Formalises second-generation leadership |
30 Sep 2025 | CS Himadri Trivedi resigns; successor appointed | Routine KMP change |
21 Sep 2026 | AGM approves higher remuneration for both MDs from 1 Aug 2026 | Follows FY2026 profit recovery |
3 Oct 2026 | CS Dhara Mistry resigns; Himandri Shah appointed | Second CS change in ~12 months |
Major Shareholders
| Holder category | Jun 2026 stake (%) | Trend |
|---|---|---|
Promoter & promoter group (Tikmani family) | 71.12 | Unchanged since FY2019 (rose from 68.27% in FY2017) |
Foreign institutional investors | 0.00 | — |
Domestic institutional investors | 0.05 | Unchanged since at least FY2017 |
Public / retail & others | 28.82 | Stable |
Number of shareholders | 3,077 | Fell from 5,665 (Sep 2025) to 3,172 (Dec 2025) — a 44% drop in one quarter without a corresponding change in public float; reason not disclosed (possibly folio consolidation or reclassification of physical holdings) |
Competitive Landscape
Key Competitors
| Competitor | Listing | Relevance | Latest revenue / scale | Positioning vs Alfa Ica |
|---|---|---|---|---|
Greenlam Industries | NSE/BSE | Market leader; among top three global laminate makers | FY2026 consolidated revenue ₹3,046 Cr; laminates & allied ₹2,433 Cr; net profit ₹56.0 Cr | ~35x Alfa's revenue; strong domestic brand, global distribution, diversified into plywood and chipboard |
Stylam Industries | NSE/BSE | Export-led laminate specialist — closest business-model peer | FY2026 total income ₹1,136 Cr; PAT ₹150 Cr; third plant in Panchkula commencing 2026 | ~13x Alfa's revenue; far superior margins (Q1 FY2026 EBITDA margin 18.7%); zero debt |
Merino Laminates (Merino Industries) | Unlisted | Large domestic and export HPL maker | Not publicly disclosed in reviewed sources | Scale and brand leader |
Royale Touche | Unlisted | Premium domestic laminate brand, strong in 1.25 mm segment | — | Premium positioning |
Century Plyboards (Century Laminates) | NSE/BSE | Laminates segment within diversified wood panels group | — | Distribution scale |
Archidply Decor | BSE | Small listed decorative laminate peer | — | Comparable micro-cap |
Bloom Dekor | BSE | Small listed laminate peer | — | Comparable micro-cap |
Deco-Mica | BSE | Small listed laminate peer (Gujarat) | — | Comparable micro-cap |
Duroply Industries | BSE | Plywood/laminates | — | Domestic brand |
Wilsonart, Formica, Abet Laminati, EGGER, Kronospan, Pfleiderer, Arpa | International | Global HPL/compact competitors in Alfa's export markets | Global scale | Alfa competes as lower-cost Indian supplier |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Alfa Ica | Greenlam Industries | Stylam Industries |
|---|---|---|---|
Revenue / total income (INR Cr) | 86.6 | 3,046.1 (consolidated) | 1,136.1 (total income) |
Revenue growth YoY (%) | 10.3 | 18.6 | ~10.0 (total income) |
EBITDA margin (%) | 4.8 (excl. other income) | ~11.0 (EBITDA before forex & exceptional ₹334.2 Cr) | — |
Net margin (%) | 2.2 | 1.8 | ~13.2 |
Net debt | ≈ ₹16.8 Cr | ₹940 Cr | Zero debt (per Q1 FY2026 disclosure) |
Export orientation | ~78% of sales | Significant international business | Majority exports (Europe, SE Asia) |



